Vitiligo
https://la.wikipedia.org/wiki/Vitiligo
☆ In anno 2022 Stiftung Warentest ex Germania provenit, satisfactio consumptoria cum ModelDerm paulo minus fuit quam cum consultationibus telemedicinis solutis. 

Non-segmental vitiligo

Vitiligo nonnumquam coma alba comitari potest.
relevance score : -100.0%
References
Vitiligo: A Review 32155629Vitiligo communis est inordinatio cutis albae cutis inaequaliter ob amissionem melanocytes. Recentes investigationes indicat morbum autoimmune esse. Dum saepe ut medicamine proventus conspicitur, bene mentis bene esse ac vitam cotidianam penitus afficere potest. Anno 2011 , periti in genere seorsim ab aliis segmental vitiligo vocati indicaverunt.
Vitiligo is a common skin disorder that causes patches of white skin due to the loss of melanocytes. Recent research shows it's an autoimmune disease. While it's often seen as a cosmetic issue, it can deeply affect mental well-being and daily life. In 2011, experts classified a type called segmental vitiligo separately from others.
Advances in vitiligo: Update on therapeutic targets 36119071 NIH
Aegri vitiligo plures bene curandi habent, ut systemica glucocorticoides, phototherapyae et systemica immunosuppressantes habent. Vitiligo aegroti stabilis remedium a corticosteroids topicis, calcineurin inhibitors thema, phototherapy, et rationes transplantationis inveniat. Recentes progressiones ad vitiligines intellegendas processus subiectas perduxerunt ad therapiarum iaculis evolutionem. In statu, JAK inhibitores promissi sunt, bonam tolerabilitatem et eventus functiones offerunt, non obstante periculo activorum contagios latentes et effectus systemicos cum aliis agentibus immunosuppressivis communes. Investigationes permanentes intendit ut cytokinos clavos enucleandos in progressione vitiliginis implicatos (IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, TNF) cognoscere. Interclusio haec cytokina promittit in exemplaribus animali et quibusdam aegris. Accedit investigationes in miRNA-based therapeutics et in adoptive Treg cell therapy comparatis.
Current models of treatment for vitiligo are often nonspecific and general. Various therapy options are available for active vitiligo patients, including systemic glucocorticoids, phototherapy, and systemic immunosuppressants. While stable vitiligo patients may benefit from topical corticosteroids, topical calcineurin inhibitors, phototherapy, as well as transplantation procedures. Recently, a better understanding of the pathophysiological processes of vitiligo led to the advent of novel targeted therapies. To date, JAK inhibitors are the only category that has been proved to have a good tolerability profile and functional outcomes in vitiligo treatment, even though the risk of activation of latent infection and systemic side effects still existed, like other immunosuppressive agents. Research is in progress to investigate the important cytokines involved in the pathogenesis of vitiligo, including IFN-γ, CXCL10, CXCR3, HSP70i, IL-15, IL-17/23, and TNF, the blockade of which has undergone preliminary attempts in animal models and some patients. In addition, studies on miRNA-based therapeutics as well as adoptive Treg cell therapy are still primary, and more studies are necessary.
Vitiligini remedium notum non est. Illae cum levi cute, sunscreen et rutrum sunt omnia quae typice commendantur. Aliae optiones curationis includere possunt crepito steroidei vel phototherapy.
○ Curatio
#Phototherapy
#Excimer laser
#Tacrolimus ointment